NB-PP_1170x120

Pharmaceutical Research and Manufacturers of America

Making health care work better for patients

Making health care work better for patients

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives. But like America’s biopharmaceutical companies, they also know those innovative medicines aren’t nearly as meaningful if they are too

PhRMA launches Medicare ad campaign for seniors

PhRMA launches Medicare ad campaign for seniors

WASHINGTON —  Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched the “Let’s Talk About Medicare” advertising campaign focused on solutions to improve affordability and predictability for seniors in Medicare Part D. Similar to how the “Let’s Talk About Cost” campaign opened up a conversation about costs and prescription drug coverage, this campaign builds on

What the budget deal means for health care

What the budget deal means for health care

WASHINGTON — Health care spending has been beefed up in some areas and reduced in others as a result of the federal budget legislation passed by Congress earlier this month. Chronic care funding was bolstered by the two-year spending plan, which was signed into law by President Trump, while some Affordable Care Act appropriations were

PhRMA strikes up drug cost conversation

PhRMA strikes up drug cost conversation

A new website from the Pharmaceutical Research and Manufacturers of America (PhRMA) aims to give consumers a better grasp of why prescription drugs cost so much in the United States. Launched this week, the LetsTalkAboutCost.org site takes an interactive approach by engaging visitors in a Q&A about the cost and coverage of prescription medications, with a goal

PhRMA takes aim at opioid abuse, misuse

PhRMA takes aim at opioid abuse, misuse

WASHINGTON —  The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a multiyear, multimillion-dollar initiative to help tackle the opioid abuse epidemic. PhRMA said this week that the effort includes a partnership with the Addiction Policy Forum to fund state and local programs, plus support for new public policies that help families and individuals

Amgen CEO elected as PhRMA chairman

Amgen CEO elected as PhRMA chairman

WASHINGTON — Pharmaceutical Research and Manufacturers of America (PhRMA) has named Amgen Inc. chairman and chief executive officer Robert Bradway as chairman-elect. Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018. Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO

Time to start sharing the Rx savings with patients

Time to start sharing the Rx savings with patients

Every day at America’s community pharmacies, patients pay a bigger and bigger share of the cost for their prescription medications. But two new studies have revealed one of the puzzling reasons why — and how market-based solutions could help ease the strain on America’s patients. Like any complex U.S. industry, the biopharmaceutical sector relies on

AAM: REMS abuse trips up new generics

AAM: REMS abuse trips up new generics

The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and

PhRMA sets new criteria for membership

PhRMA sets new criteria for membership

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) this week approved new criteria for membership. With the move, biopharmaceutical companies will have to meet new research-and-development requirements to be eligible to join the organization. PhRMA said the updated membership criteria, which go into effect immediately, came after a three-month review by its board

PhRMA campaign takes aim at negotiated Rx rebates

PhRMA campaign takes aim at negotiated Rx rebates

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) has kicked off “Share the Savings,” a new campaign to educate consumers about the lack of drug rebate pass-through for commercially insured patients with high deductibles and coinsurance. PhRMA said a collection of advertisements will be featured in print, radio, digital and social channels throughout

Good news in Rx: Treatment options keep growing

Good news in Rx: Treatment options keep growing

When chain drug store customers are waiting in line at the pharmacy, odds are they have at least one thing on their mind: relief for their disease or condition. The good news is that at the start of 2017, America’s chain drug store customers will see more available treatment options than at any other time

PhRMA elects officers, welcomes new member UCB

PhRMA elects officers, welcomes new member UCB

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors has elected new officers and ushered in a new member company. Joaquin Duato, worldwide chairman of pharmaceuticals at Johnson & Johnson, was elected chairman. Joseph Jimenez, chief executive officer of Novartis AG, was elected chairman-elect, and Amgen chairman and CEO Robert Bradway

President Trump meets with pharma industry

President Trump meets with pharma industry

In a meeting with pharmaceutical industry leaders, President Donald Trump decried the high cost of drugs but said his administration would work to make it easier to get new, innovative medications to market. The Pharmaceutical Research and Manufacturers of America (PhRMA), which along with drug company executives met with Trump at the White House on

Rising rebates squeeze branded drug makers

Rising rebates squeeze branded drug makers

WASHINGTON — Branded drug manufacturers are shelling out higher rebates and discounts on medications and seeing their share of prescription drug sales shrink, according to a study commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA said Wednesday that the study, conducted by Berkeley Research Group (BRG), is among the first to gauge